IDEAYA Biosciences, Inc. (IDYA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Yujiro S. Hata.
IDYA hat IPO-Datum 2019-05-23, 131 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $2.84B.
IDEAYA Biosciences is a precision medicine oncology company focused on synthetic lethality, developing targeted cancer therapeutics for patient populations selected through molecular diagnostics. The company's lead candidates include IDE397, a methionine adenosyltransferase 2a inhibitor in Phase I trials for solid tumors with MTAP deletions, and IDE196, a protein kinase C inhibitor in Phase I/II trials for cancers with GNAQ or GNA11 mutations. Its preclinical pipeline targets multiple synthetic lethality pathways, including PARG inhibitors, Pol Theta inhibitors for BRCA-deficient tumors, and WRN inhibitors for microsatellite instability-high cancers. The company collaborates with leading organizations including Cancer Research UK, the University of Manchester, Pfizer, and GlaxoSmithKline. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA is advancing precision oncology through genetically-defined patient selection and targeted drug development.
